Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa
Identifieur interne : 002815 ( Main/Exploration ); précédent : 002814; suivant : 002816Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa
Auteurs : F. Boomsma [Pays-Bas] ; D. Meerwaldt [Pays-Bas] ; J. Man In'T Veld [Pays-Bas] ; A. Hovestadt [Pays-Bas] ; H. Schalekamp [Pays-Bas]Source :
- Journal of Neurology [ 0340-5354 ] ; 1989-05-01.
Abstract
Summary: The effect of levodopa (l-dopa), alone or in combination with a peripheral decarboxylase inhibitor (PDI), on plasma levels of aromatic-l-amino acid decarboxylase (ALAAD, = dopa decarboxylase), l-dopa, 3-O-methyl-dopa (3-OMD), dopamine (DA), noradrenaline, adrenaline and dopamine beta-hydroxylase has been studied. In healthy subjects and in patients with parkinsonism plasma ALAAD level fell after administration of l-dopa + benserazide, but returned to previous levels within 90 min. In a cross-sectional study blood was obtained, 2 h after dosing, from 104 patients with idiopathic parkinsonism, divided into four groups: no l-dopa treatment (group 1), l-dopa alone (group 2), l-dopa + benserazide (Madopar) (group 3) and l-dopa + carbidopa (Sinemet) (group 4). Plasma ALAAD, which was normal in groups 1 and 2, was increased 3-fold in groups 3 and 4, indicating that there was induction of ALAAD by the co-administration of PDI. Despite this induction of ALAAD, in groups 3 and 4, with half the daily l-dopa dose compared with group 2, plasma l-dopa and 3-OMD levels were 5 times higher, while plasma DA levels were not different. The DA/l-dopa ratio was decreased 5-fold in group 2 and 16-fold in groups 3 and 4 as compared with group 1. Neither 3-OMD levels nor 3-OMD/l-dopa ratios correlated with the occurrence of on-off fluctuations. In a longitudinal study of three patients started on Madopar treatment the induction of plasma ALAAD was found to occur gradually over 3–4 weeks. Further detailed pharmacokinetic studies in plasma and cerebrospinal fluid are required in order to elucidate whether the ALAAD induction by PDI may be related to the loss of clinical efficacy of combination therapy in some patients and how it is related to end-of-dose deterioration and on-off phenomena.
Url:
DOI: 10.1007/BF00314504
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa</title><author><name sortKey="Boomsma, F" sort="Boomsma, F" uniqKey="Boomsma F" first="F." last="Boomsma">F. Boomsma</name></author><author><name sortKey="Meerwaldt, D" sort="Meerwaldt, D" uniqKey="Meerwaldt D" first="D." last="Meerwaldt">D. Meerwaldt</name></author><author><name sortKey="Man In T Veld, J" sort="Man In T Veld, J" uniqKey="Man In T Veld J" first="J." last="Man In'T Veld">J. Man In'T Veld</name></author><author><name sortKey="Hovestadt, A" sort="Hovestadt, A" uniqKey="Hovestadt A" first="A." last="Hovestadt">A. Hovestadt</name></author><author><name sortKey="Schalekamp, H" sort="Schalekamp, H" uniqKey="Schalekamp H" first="H." last="Schalekamp">H. Schalekamp</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:654C55C4F411130E880C734E3523545BBADEDC9E</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1007/BF00314504</idno><idno type="url">https://api.istex.fr/document/654C55C4F411130E880C734E3523545BBADEDC9E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002C47</idno><idno type="wicri:Area/Main/Curation">002878</idno><idno type="wicri:Area/Main/Exploration">002815</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa</title><author><name sortKey="Boomsma, F" sort="Boomsma, F" uniqKey="Boomsma F" first="F." last="Boomsma">F. Boomsma</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine I, Erasmus University, Dr. Molewaterplein 40, 3015 GD, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Meerwaldt, D" sort="Meerwaldt, D" uniqKey="Meerwaldt D" first="D." last="Meerwaldt">D. Meerwaldt</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Hospital Dijkzigt, Erasmus University, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Man In T Veld, J" sort="Man In T Veld, J" uniqKey="Man In T Veld J" first="J." last="Man In'T Veld">J. Man In'T Veld</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine I, Erasmus University, Dr. Molewaterplein 40, 3015 GD, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Hovestadt, A" sort="Hovestadt, A" uniqKey="Hovestadt A" first="A." last="Hovestadt">A. Hovestadt</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Hospital Dijkzigt, Erasmus University, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Schalekamp, H" sort="Schalekamp, H" uniqKey="Schalekamp H" first="H." last="Schalekamp">H. Schalekamp</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine I, Erasmus University, Dr. Molewaterplein 40, 3015 GD, Rotterdam</wicri:regionArea><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology</title><title level="j" type="abbrev">J Neurol</title><idno type="ISSN">0340-5354</idno><idno type="eISSN">1432-1459</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1989-05-01">1989-05-01</date><biblScope unit="volume">236</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="223">223</biblScope><biblScope unit="page" to="230">230</biblScope></imprint><idno type="ISSN">0340-5354</idno></series><idno type="istex">654C55C4F411130E880C734E3523545BBADEDC9E</idno><idno type="DOI">10.1007/BF00314504</idno><idno type="ArticleID">Art9</idno><idno type="ArticleID">BF00314504</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0340-5354</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: The effect of levodopa (l-dopa), alone or in combination with a peripheral decarboxylase inhibitor (PDI), on plasma levels of aromatic-l-amino acid decarboxylase (ALAAD, = dopa decarboxylase), l-dopa, 3-O-methyl-dopa (3-OMD), dopamine (DA), noradrenaline, adrenaline and dopamine beta-hydroxylase has been studied. In healthy subjects and in patients with parkinsonism plasma ALAAD level fell after administration of l-dopa + benserazide, but returned to previous levels within 90 min. In a cross-sectional study blood was obtained, 2 h after dosing, from 104 patients with idiopathic parkinsonism, divided into four groups: no l-dopa treatment (group 1), l-dopa alone (group 2), l-dopa + benserazide (Madopar) (group 3) and l-dopa + carbidopa (Sinemet) (group 4). Plasma ALAAD, which was normal in groups 1 and 2, was increased 3-fold in groups 3 and 4, indicating that there was induction of ALAAD by the co-administration of PDI. Despite this induction of ALAAD, in groups 3 and 4, with half the daily l-dopa dose compared with group 2, plasma l-dopa and 3-OMD levels were 5 times higher, while plasma DA levels were not different. The DA/l-dopa ratio was decreased 5-fold in group 2 and 16-fold in groups 3 and 4 as compared with group 1. Neither 3-OMD levels nor 3-OMD/l-dopa ratios correlated with the occurrence of on-off fluctuations. In a longitudinal study of three patients started on Madopar treatment the induction of plasma ALAAD was found to occur gradually over 3–4 weeks. Further detailed pharmacokinetic studies in plasma and cerebrospinal fluid are required in order to elucidate whether the ALAAD induction by PDI may be related to the loss of clinical efficacy of combination therapy in some patients and how it is related to end-of-dose deterioration and on-off phenomena.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country><region><li>Hollande-Méridionale</li></region><settlement><li>Rotterdam</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Boomsma, F" sort="Boomsma, F" uniqKey="Boomsma F" first="F." last="Boomsma">F. Boomsma</name></region><name sortKey="Hovestadt, A" sort="Hovestadt, A" uniqKey="Hovestadt A" first="A." last="Hovestadt">A. Hovestadt</name><name sortKey="Man In T Veld, J" sort="Man In T Veld, J" uniqKey="Man In T Veld J" first="J." last="Man In'T Veld">J. Man In'T Veld</name><name sortKey="Meerwaldt, D" sort="Meerwaldt, D" uniqKey="Meerwaldt D" first="D." last="Meerwaldt">D. Meerwaldt</name><name sortKey="Schalekamp, H" sort="Schalekamp, H" uniqKey="Schalekamp H" first="H." last="Schalekamp">H. Schalekamp</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002815 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002815 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:654C55C4F411130E880C734E3523545BBADEDC9E
|texte= Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa
}}
| This area was generated with Dilib version V0.6.23. |  |